TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35667713

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physical activity recommendations (Control)
Number of subjects: 0
Study: 32658496

Group type: EXPERIMENTAL
Intervention: High‐intensive feedback condition
Number of subjects: 368

Group type: COMPARATOR
Intervention: Low‐intensive monitoring of progress (control condition)
Number of subjects: 368
Study: 35250329

Group type: EXPERIMENTAL
Intervention: Self‐ and manual massage (SMM) on the plantar surface of the dominant leg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (non‐dominant leg, no SMM)
Number of subjects: 17
Study: 32753447

Group type: EXPERIMENTAL
Intervention: Cinacalcet plus conventional therapy (cinacalcet strategy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (standard strategy)
Number of subjects: 0
Study: 34991145

Group type: EXPERIMENTAL
Intervention: Symptoms presentation in patients with tumors 10 cm or smaller
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Symptoms presentation in patients with tumors larger than 10 cm to 15 cm
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Symptoms presentation in patients with tumors larger than 15 cm
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Overall symptom presentation
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Association of symptoms with recurrence or survival
Number of subjects: 419
Study: 32867707

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 18
Study: 34867291

Group type: EXPERIMENTAL
Intervention: CCT with active tDCS
Number of subjects: 46

Group type: COMPARATOR
Intervention: CCT with sham tDCS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Watching educational videos with sham tDCS
Number of subjects: 46
Study: 34910186

Group type: EXPERIMENTAL
Intervention: ShipShape study participants (n=147)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Non-enrolled SMs (n=38)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Navy HRBS respondents (n=164)
Number of subjects: 225
Study: 34425883

Group type: EXPERIMENTAL
Intervention: Varoglutamstat (PQ912)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32498073

Group type: EXPERIMENTAL
Intervention: Pharmacological challenges to suppress the HPA axis prior to stress exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological challenges to suppress the SNS prior to stress exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (baseline activation of SNS or HPA observed)
Number of subjects: 0
Study: 35212573

Group type: EXPERIMENTAL
Intervention: Baseline depression and anxiety
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Baseline sleep disturbance
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Urinary symptom severity
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Baseline depression, anxiety, sleep disturbance, and physical function measures
Number of subjects: 518
Study: 32991033

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEi)
Number of subjects: 252

Group type: COMPARATOR
Intervention: No ACEi
Number of subjects: 252
Study: 35655728

Group type: EXPERIMENTAL
Intervention: Thoracoscopy-assisted rib internal fixation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional open reduction and internal fixation
Number of subjects: 100
Study: 33811049

Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (ABI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 180
Study: 32066536

Group type: EXPERIMENTAL
Intervention: Subcutaneous reslizumab 110 mg
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 34260265

Group type: EXPERIMENTAL
Intervention: CMB305 with atezolizumab (experimental arm)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Atezolizumab alone (control arm)
Number of subjects: 89
Study: 33877678

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus reuteri LRE02 and Lactobacillus rhamnosus LR04)
Number of subjects: 0
Study: 36094625

Group type: EXPERIMENTAL
Intervention: Shunt Occlusion (SO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard Medical Treatment (SMT)
Number of subjects: 40
Study: 34146343

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (optimally effective)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (improvement-type model)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (adjusted for treatment discontinuation, remission-type model)
Number of subjects: 2201

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy (adjusted for treatment discontinuation, improvement-type model)
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2201
Study: 32623182

Group type: EXPERIMENTAL
Intervention: Gemcitabine + nab-paclitaxel for 2 months then FOLFIRI.3 for 2 months (Arm A)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Gemcitabine + nab-paclitaxel alone until progression (Arm B)
Number of subjects: 127
Study: 35466623

Group type: EXPERIMENTAL
Intervention: Reverse Tenzel flap
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cutler Beard flap
Number of subjects: 60
Study: 32297486

Group type: EXPERIMENTAL
Intervention: brexpiprazole 1 mg/day, increased to 2 mg/day by week 4, up to 4 mg/day according to CGI-I criteria
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: brexpiprazole
Number of subjects: 200
Study: 35830641

Group type: EXPERIMENTAL
Intervention: Erythropoietin (1000 U/kg) administered intravenously within 26 hours after birth and at 2, 3, 4, and 7 days of age
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo (saline) administered intravenously within 26 hours after birth and at 2, 3, 4, and 7 days of age
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 32430340

Group type: EXPERIMENTAL
Intervention: YAG laser peripheral iridotomy (LPI)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Control (fellow eye without LPI)
Number of subjects: 875
Study: 32077353

Group type: EXPERIMENTAL
Intervention: Endovascular therapy decisions under assumed ideal conditions
Number of subjects: 607

Group type: COMPARATOR
Intervention: Endovascular therapy decisions under current local resources
Number of subjects: 607
Study: 34999737

Group type: EXPERIMENTAL
Intervention: Oral THC
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Functional near-infrared spectroscopy (fNIRS)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Drug Recognition Evaluator-conducted expanded field sobriety examination
Number of subjects: 169
Study: 36053616

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion of local anaesthetic (bupivacaine) for the first 72 hours along with systemic opioid analgesia (catheter group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Only systemic opioid analgesia (opioid group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 32379666

Group type: EXPERIMENTAL
Intervention: Acupressure applied to five acupressure points on the arms and shoulders, for six weeks, three days per week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 50
Study: 36002844

Group type: EXPERIMENTAL
Intervention: Flavour School programme (experimental group)
Number of subjects: 400

Group type: COMPARATOR
Intervention: No intervention with normal school teaching (control group)
Number of subjects: 400
Study: 33796948

Group type: EXPERIMENTAL
Intervention: Physical activity (6 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 37
Study: 32667564

Group type: EXPERIMENTAL
Intervention: Women affected by the earthquake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender as a social determinant
Number of subjects: 0
Study: 34599935

Group type: EXPERIMENTAL
Intervention: Tele-collaborative specialty care
Number of subjects: 220

Group type: COMPARATOR
Intervention: Electronic consultation
Number of subjects: 220
Study: 33388765

Group type: EXPERIMENTAL
Intervention: Simulator (SIM) group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 58
Study: 32213300

Group type: EXPERIMENTAL
Intervention: Attractive food items
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Convenient food items
Number of subjects: 172

Group type: COMPARATOR
Intervention: Type of diagnostic group (ADHD vs. non-ADHD)
Number of subjects: 172
Study: 34398809

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 64
Study: 32243865

Group type: EXPERIMENTAL
Intervention: Landiolol (1 μg/kg per min, IV infusion, can be increased to a maximum of 20 μg/kg per min)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control (conventional sepsis therapy)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study: 35057451

Group type: EXPERIMENTAL
Intervention: mHealth intervention with app and activity tracker for 3 months
Number of subjects: 650

Group type: COMPARATOR
Intervention: Brief advice about diet and exercise
Number of subjects: 650
Study: 33419426

Group type: EXPERIMENTAL
Intervention: Isotoner® arthritis gloves (23-32 mmHg pressure)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Loose-fitting placebo gloves (providing no/minimal pressure)
Number of subjects: 206
Study: 35113614

Group type: EXPERIMENTAL
Intervention: Porchlight Project intervention providing training to volunteers for dementia capable support
Number of subjects: 0
Study: 32210538

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid modified, irinotecan and gene co-loaded lipid-polymer hybrid nanocarriers (HA-I/D-LPNs)
Number of subjects: 0
Study: 34860481

Group type: EXPERIMENTAL
Intervention: Intracameral phenylephrine 1.0%-ketorolac 0.3% (P/K)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 56
Study: 33089315

Group type: EXPERIMENTAL
Intervention: Hypocellular AML
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonhypocellular AML
Number of subjects: 25
Study: 32343623

Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Number of subjects: 9

Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise
Number of subjects: 9
Study: 34033934

Group type: EXPERIMENTAL
Intervention: ICG-PDT + PIMD
Number of subjects: 48

Group type: COMPARATOR
Intervention: PIMD
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ICG-PDT
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 35854764

Group type: EXPERIMENTAL
Intervention: New nursing team management mode
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional nursing management
Number of subjects: 100
Study: 34157613

Group type: EXPERIMENTAL
Intervention: BioNTech (Germany)
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Pfizer (U.S.)
Number of subjects: 1243

Group type: COMPARATOR
Intervention: General animus toward the other foreign country
Number of subjects: 1243
Study: 32074684

Group type: COMPARATOR
Intervention: Mosapride group (Mosapride citrate tablets 5 mg 3 times per day for 2 weeks)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Combizym(®) group (Combizym tablets 244 mg 3 times per day for 2 weeks)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Combined treatment group (both drugs at same doses for 2 weeks)
Number of subjects: 323
Study: 36127661

Group type: EXPERIMENTAL
Intervention: Bumetanide plus chlorthalidone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bumetanide plus placebo
Number of subjects: 32
Study: 33629816

Group type: EXPERIMENTAL
Intervention: Talking With Voices intervention
Number of subjects: 50
Study: 32446770

Group type: EXPERIMENTAL
Intervention: Surgical Exploration And Discovery (SEAD) program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (instruction manual only)
Number of subjects: 62
Study: 35105521

Group type: EXPERIMENTAL
Intervention: Fluorouracil/leucovorin + oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) plus bevacizumab, cetuximab or both
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Age ≥ 70
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Presence of comorbidities
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Age and comorbidities
Number of subjects: 1345
Study: 33872182

Group type: EXPERIMENTAL
Intervention: Zemedy app (CBT program)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 121
Study: 32807229

Group type: EXPERIMENTAL
Intervention: Integrative medicine rehabilitation (IMR) with usual rehabilitation (UR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual rehabilitation (UR)
Number of subjects: 80
Study: 36094054

Group type: EXPERIMENTAL
Intervention: Honey-rich energy drink (BeeBad EnegyDrink®, Parodi Group, Italy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Popular energy drink with free sugars
Number of subjects: 15
Study: 33263957

Group type: EXPERIMENTAL
Intervention: Early detection of prostate cancer through prostate specific antigen screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prostate specific antigen screening
Number of subjects: 0
Study: 35745123

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and education
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard care for wound treatment
Number of subjects: 29
Study: 32534040

Group type: EXPERIMENTAL
Intervention: Resveratrol (250 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 33569986

Group type: EXPERIMENTAL
Intervention: FTD/TPI plus bevacizumab
Number of subjects: 490

Group type: COMPARATOR
Intervention: FTD/TPI monotherapy
Number of subjects: 490
Study: 36355369

Group type: EXPERIMENTAL
Intervention: Higher protein formula
Number of subjects: 1678

Group type: COMPARATOR
Intervention: Lower protein formula
Number of subjects: 1678

Group type: COMPARATOR
Intervention: Breastfed reference group
Number of subjects: 1678
Study: 33076983

Group type: EXPERIMENTAL
Intervention: Multidomain intervention (MI)
Number of subjects: 67

Group type: COMPARATOR
Intervention: No MI group (Control)
Number of subjects: 67
Study: 32866688

Group type: EXPERIMENTAL
Intervention: Novel camera system
Number of subjects: 16
Study: 33168092

Group type: EXPERIMENTAL
Intervention: Sub-optimal infant and young child feeding practices
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Husband being a government employee
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Lower household income
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Not attending antenatal care
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Child age 0-5 months
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Negative attitude towards infant and young child feeding practices
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Number of children 3-4
Number of subjects: 418
Study: 33548936

Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (coconut oil)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Overall cohort (preoperative vs postoperative)
Number of subjects: 49
Study: 32482095

Group type: EXPERIMENTAL
Intervention: 40 g protein post-exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: 20 g protein post-exercise
Number of subjects: 18
Study: 35384190

Group type: EXPERIMENTAL
Intervention: Digital feedback
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Putty index
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Digital and putty index assessment
Number of subjects: 48

Group type: COMPARATOR
Intervention: No guide (control)
Number of subjects: 48
Study: 32266765

Group type: EXPERIMENTAL
Intervention: Therapy dog interaction for 5 minutes
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Coloring a mandala for 5 minutes
Number of subjects: 122

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Therapy dog interaction and coloring
Number of subjects: 122
Study: 35461789

Group type: EXPERIMENTAL
Intervention: Educational intervention using problematization methodology in 6 educational groups
Number of subjects: 41

Group type: COMPARATOR
Intervention: Routine consultations (Control)
Number of subjects: 41
Study: 33587394

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 to 20 mg/d)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 33380580

Group type: EXPERIMENTAL
Intervention: Hydrogen inhalation (66.7% hydrogen and 33.3% oxygen, 3 L/min for 4 hours each day for 2 weeks)
Number of subjects: 20
Study: 34245302

Group type: EXPERIMENTAL
Intervention: Acceptance-based treatment (ABT)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard behavioral treatment (SBT)
Number of subjects: 189
Study: 32278648

Group type: EXPERIMENTAL
Intervention: Pulse oximeter readings under the tail
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pulse oximeter readings at the ear
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pulse oximeter readings at the cheek
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pulse oximeter readings inside the rectum
Number of subjects: 16
Study: 97426120

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy
Number of subjects: 183
Study: 35709811

Group type: EXPERIMENTAL
Intervention: HPV 16 and 18 AS04-adjuvanted vaccine
Number of subjects: 7466

Group type: COMPARATOR
Intervention: Hepatitis A virus vaccine (control)
Number of subjects: 7466
Study: 33578191

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 33166307

Group type: EXPERIMENTAL
Intervention: Intranasal GSK2245035 20 ng once weekly for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 34111361

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) in the form of bilevel positive airway pressure (BPAP) or continuous positive airway pressure (CPAP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 101
Study: 34491016

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 50 U
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 75 U
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 100 U
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 125 U
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (all doses)
Number of subjects: 399
Study: 34501925

Group type: EXPERIMENTAL
Intervention: Oral health intervention (oral health assessment, dental treatment recommendations, oral health education)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 527
Study: 32538682

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic radical nephroureterectomy (TLNU)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic radical nephroureterectomy (RLNU)
Number of subjects: 48
Study: 32349606

Group type: EXPERIMENTAL
Intervention: Transvaginal appendicectomy using innovative strategically designed submucosal tunnels
Number of subjects: 18
Study: 35175218

Group type: EXPERIMENTAL
Intervention: Intranasal gel with a bacteriophages mixture (Otofag, Micromir, Russia) twice a day for ten weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33283986

Group type: EXPERIMENTAL
Intervention: Universal test and treat (UTT) intervention
Number of subjects: 144
Study: 35538296

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 35 mg twice daily
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 32567065

Group type: EXPERIMENTAL
Intervention: WeChat WeQuit intervention (2 weeks pre- and 12 weeks post-quit)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (digital booklet of 'Happy Quit')
Number of subjects: 2000
Study: 33034301

Group type: EXPERIMENTAL
Intervention: Intact umbilical cord milking (MUC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC)
Number of subjects: 144
Study: 34091518

Group type: EXPERIMENTAL
Intervention: Augmented information (education about nocebo effects)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard information (describing benefits and risks of TCAs)
Number of subjects: 31
Study: 32543020

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg orally daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Furosemide 5 mg/h intravenously
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 33

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 33
Study: 36171101

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) before EVT
Number of subjects: 639
Study: 34146033

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1% drop
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Tropicamide 0.5% drop
Number of subjects: 129

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 129
Study: 32333590

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (12-week internet-based program, 40 minutes per day, 4 days a week)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Active-control group (details not specified)
Number of subjects: 260
Study: 35462369

Group type: EXPERIMENTAL
Intervention: Desidustat oral tablets (thrice a week) for 24 weeks
Number of subjects: 392

Group type: COMPARATOR
Intervention: Epoetin alfa subcutaneous injection for 24 weeks
Number of subjects: 392
Study: 33067129

Group type: EXPERIMENTAL
Intervention: Fortified yogurt with 3 g HMB, 1000 IU vitamin D, and 500 mg vitamin C
Number of subjects: 66
Study: 35871650

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) for 3 weeks (daily food intake within 10 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (spreading food intake over ≥14 h)
Number of subjects: 14
Study: 34700294

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg sodium, two capsules per day for five days)
Number of subjects: 0
Study: 33590799

Group type: EXPERIMENTAL
Intervention: aRCT + HCQ + BEV
Number of subjects: 42

Group type: COMPARATOR
Intervention: aRCT + BEV
Number of subjects: 42